Quantum Cyber N.V. (QUCY) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Quantum Cyber N.V. (QUCY) has outperformed Unicycive Therapeutics (UNCY) over the past year, losing 13.1% versus a loss of 14.7%. Quantum Cyber N.V. is the larger company by market cap ($113.5 million vs $112.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QUCY | UNCY |
|---|---|---|
| Share price | $1.35 | $4.11 |
| Market cap | $113.49M | $112.59M |
| 1-day change | -2.88% | +0.98% |
| YTD return | +24.11% | -29.46% |
| 1-year return | -13.13% | -14.68% |
| 5-year return | — | -85.06% |
| Forward P/E | — | 2.44 |
| EPS (TTM) | $-2.41 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.93 | $8.74 |
| 52-week low | $0.30 | $3.93 |
| Distance from 52-week high | -72.62% | -52.97% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +566.67% | +591.00% |
| Average volume | 691.24K | 839.29K |
| Shares outstanding | 84.07M | 27.39M |
| Employees | 10 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Quantum Cyber N.V.
QUCY stock →Quantum Cyber N.V. operates as a technology company focused on cybersecurity and quantum computing solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
QUCY vs UNCY FAQ
Which is bigger, Quantum Cyber N.V. or Unicycive Therapeutics?
Quantum Cyber N.V. (QUCY) is larger, with a market capitalization of $113.49M compared with $112.59M for Unicycive Therapeutics (UNCY).
Which stock has performed better over the past year, QUCY or UNCY?
QUCY returned -13.13% over the past 12 months, compared with -14.68% for UNCY (price return, excluding dividends). Past performance does not predict future results.
Are Quantum Cyber N.V. and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.